Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10525356 | 0.91 | TLR8 (0.46) | CYP1A2CYP3A4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL2127539 | 0.89 | SLC6A4 (0.44) | CYP1A2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22169453 | 0.88 | POLB (0.57) | CYP1A2CYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22169514 | 0.88 | NCOA1 (0.42) | CYP1A2CYP3A4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22904301 | 0.88 | TLR8 (0.44) | CYP1A2CYP3A4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL2072019 | 0.88 | ALDH1A1 (0.44) | CYP1A2CYP3A4SLC6A4CYP2C19SMN1; SMN2 | |
| SCHEMBL17427513 | 0.87 | KDM4E (0.45) | CYP1A2SLC6A4CYP2C19SMN1; SMN2POLB | |
| SCHEMBL17085521 | 0.85 | KDM4E (0.41) | HTR1ASLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL22904601 | 0.85 | VEGFA (0.51) | HTR1ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL31297748 | 0.85 | MEN1 (0.37) | CYP1A2CYP3A4HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856734-B1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-07-20 | — | — | US | disclosed |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-21 | — | — | US | disclosed |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-3856734-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | Studiengesellschaft Kohle mbH (DE) | 2021-08-04 | — | — | EP | disclosed |
| EP-1014953-B1 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| WO-2004113303-A1 | INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-6696482-B2 | QUINAZOLINE, NITROTHIAZOLE AND INDOLINONE BASED HYDROPHOBIC FORMULATIONS FOR ORAL ADMINISTRATION FOR TREATING CELL PROLIFERATION DISORDER IN A MAMMAL | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | SHENOY NARMADA (US) | 2001-08-09 | — | — | US | disclosed |
| US-6248771-B1 | MIXTURE CONTAINING SURFACTANT; ANTIPROLIFERATIVE AGENTS; KINASE INHIBITOR | SUGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-1014953-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | Sugen, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998038984-A2 | FORMULATIONS FOR HYDROPHOBIC PHARMACEUTICAL AGENTS | SUGEN, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012844-A1 | Formulations for hydrophobic pharmaceutical agents | ABCG2, SLC7A5, SLCO4C1 | CYP1A2 210/4885CYP3A4 22/4885HTR1A 94/4885 |
| US-20230227425-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | CYP1A2 552/4885CYP3A4 241/4885HTR1A 2427/4885 |
| US-20220002263-A1 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | CFH, DOHH, CTSH | CYP1A2 552/4885CYP3A4 241/4885HTR1A 2427/4885 |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | CYP1A2 4779/4885CYP3A4 4762/4885HTR1A 3774/4885 |
| US-11608322-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | CYP1A2 659/4885CYP3A4 294/4885HTR1A 2493/4885 |
| US-12065422-B2 | Reagents and process for direct C—H functionalization | CFH, DOHH, CTSH | CYP1A2 659/4885CYP3A4 294/4885HTR1A 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.